PharmaCyte Biotech, Inc.

Nasdaq:PMCB

Biological Products, (No Diagnostic Substances)·LAS VEGAS, NV

CEO

Silverman Joshua

Summary Financials

Revenue

FY 2025

Adj. EBITDA

-$8.5M

FY 2025

Net Income

$333,763

FY 2025

EPS (Diluted)

-$1.80

FY 2025

Stock Price

$0.77

+18.0%

2026-03-06

52W Range

$0.63 – $1.82

P/E Ratio

-0.4x

Market Cap

$7.8M

Cash

$50.2M

FY 2025

Total Debt

$20,000

FY 2013

Net Cash

$50.2M

FY 2013

Enterprise Value

-$42.4M

Debt / EBITDA

5.9x

FY 2025

EV / EBITDA

5.0x

Employees

—

Revenue

FY 2025

Adj. EBITDA

-$8.5M

FY 2025

Net Income

$333,763

FY 2025

EPS (Diluted)

-$1.80

FY 2025

Stock Price

$0.77

+18.0%

2026-03-06

52W Range

$0.63 – $1.82

P/E Ratio

-0.4x

Market Cap

$7.8M

Cash

$50.2M

FY 2025

Total Debt

$20,000

FY 2013

Net Cash

$50.2M

FY 2013

Enterprise Value

-$42.4M

Debt / EBITDA

5.9x

FY 2025

EV / EBITDA

5.0x

Employees

—